Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial
Stroke · 2023-12 · 54 (12) · 2962-2971
DOI: 10.1161/strokeaha.123.044568 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, online erschienen am 28.11.2023. Verfasst von Christopher F Bladin und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Department of Neurology, Monash University, Clayton, Victoria, Austra…. Hauptthemen laut MEDLINE: Ischemic Stroke, Stroke, Hyperglycemia, Hypoglycemia. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Hyperglycemia in acute ischemic stroke reduces the efficacy of stroke thrombolysis and thrombectomy, with worse clinical outcomes. Insulin-based therapies are difficult to implement and may cause hypoglycemia. We investigated whether exenatide, a GLP-1 (glucagon-like peptide-1) receptor agonist, would improve stroke outcomes, and control poststroke hyperglycemia with minimal hypoglycemia. METHODS: The TEXAIS trial (Treatment With Exenatide in Acute Ischemic Stroke) was an international, multicenter, phase 2 prospective randomized clinical trial (PROBE [Prospective Randomized Open Blinded End-Point] design) enrolling adult patients with acute ischemic stroke ≤9 hours of stroke onset to receive exenatide (5 µg BID subcutaneous injection) or standard care for 5 days, or until hospital discharge (whichever sooner). The primary outcome (intention to treat) was the proportion of patients with ≥8-point improvement in National Institutes of Health Stroke Scale score (or National Institutes of Health Stroke Scale scores 0–1) at 7 days poststroke. Safety outcomes included death, episodes of hyperglycemia, hypoglycemia, and adverse event. RESULTS: From April 2016 to June 2021, 350 patients were randomized (exenatide, n=177, standard care, n=173). Median age, 71 years (interquartile range, 62–79), median National Institutes of Health Stroke Scale score, 4 (interquartile range, 2–8). Planned recruitment (n=528) was stopped early due to COVID-19 disruptions and funding constraints. The primary outcome was achieved in 97 of 171 (56.7%) in the standard care group versus 104 of 170 (61.2%) in the exenatide group (adjusted odds ratio, 1.22 [95% CI, 0.79–1.88]; P =0.38). No differences in secondary outcomes were observed. The per-patient mean daily frequency of hyperglycemia was significantly less in the exenatide group across all quartiles. No episodes of hypoglycemia were recorded over the treatment period. Adverse events of mild nausea and vomiting occurred in 6 (3.5%) exenatide patients versus 0 (0%) standard care with no withdrawal. CONCLUSIONS: Treatment with exenatide did not reduce neurological impairment at 7 days in patients with acute ischemic stroke. Exenatide did significantly reduce the frequency of hyperglycemic events, without hypoglycemia, and was safe to use. Larger acute stroke trials using GLP-1 agonists such as exenatide should be considered. REGISTRATION: URL: www.australianclinicaltrials.gov.au; Unique identifier: ACTRN12617000409370. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03287076.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Department of Neurology, Monash University, Clayton, Victoria, Australia (C.F.B., H.M.D., P.M.C.C.).
- The Florey Institute of Neuroscience and Mental Health (C.F.B., V.T., B.C.V.C.), University of Melbourne, Parkville, Australia.
- Faculty of Medicine and Health, Westmead Hospital (N.W.C.), University of Sydney, New South Wales, Australia.
- Department of Medicine (L.C.), University of Melbourne, Parkville, Australia.
- Australian Centre for Accelerating Diabetes Innovations (L.C., E.E.), University of Melbourne, Parkville, Australia.
- Austin Health, Australia (L.C., E.E.).
ORCID-Profile: Christopher F Bladin, Ngai Wah Cheung, Helen M Dewey, Leonid Churilov, Vincent Thijs, Elif Ekinci, Christopher R Levi, Richard Lindley, Geoffrey A Donnan, Mark W Parsons, Atte Meretoja, Marjaana Tiainen, Philip M C Choi, Dennis Cordato, Helen Brown, Bruce C V Campbell, Stephen M Davis, Geoffrey Cloud, Rohan Grimley, Darshan Ghia, Lauren Sanders, Romesh Markus, Claire Muller, Patrick Salvaris, Teddy Wu
Zitieren
APA
Bladin, C. F., Wah Cheung, N., Dewey, H. M., Churilov, L., Middleton, S., Thijs, V., Ekinci, E., Levi, C. R., Lindley, R., Donnan, G. A., Parsons, M. W., Meretoja, A., Tiainen, M., Choi, P. M. C., Cordato, D., Brown, H., Campbell, B. C. V., Davis, S. M., Cloud, G., …, & TEXAIS Investigators (2023). Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial. Stroke, 54(12), 2962-2971. https://doi.org/10.1161/strokeaha.123.044568
Vancouver
Bladin CF, Wah Cheung N, Dewey HM, Churilov L, Middleton S, Thijs V, et al. Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial. Stroke. 2023;54(12):2962-2971. doi:10.1161/strokeaha.123.044568
BibTeX
@article{Bladin2023,
author = {Bladin, Christopher F and Wah Cheung, Ngai and Dewey, Helen M and Churilov, Leonid and Middleton, Sandy and Thijs, Vincent and Ekinci, Elif and Levi, Christopher R and Lindley, Richard and Donnan, Geoffrey A and Parsons, Mark W and Meretoja, Atte and Tiainen, Marjaana and Choi, Philip M C and Cordato, Dennis and Brown, Helen and Campbell, Bruce C V and Davis, Stephen M and Cloud, Geoffrey and Grimley, Rohan and Lee-Archer, Matthew and Ghia, Darshan and Sanders, Lauren and Markus, Romesh and Muller, Claire and Salvaris, Patrick and Wu, Teddy and Fink, John and TEXAIS Investigators, TEXAIS Investigators},
title = {Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial},
journal = {Stroke},
year = {2023},
volume = {54},
number = {12},
pages = {2962--2971},
doi = {10.1161/strokeaha.123.044568}
}
EUVIMED